Updated Results of TCAR Surveillance Project Presented at 2019 VEITHsymposium
NEW YORK, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the VEITHsymposium. In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project contemporaneously comparing TCAR to the surgical standard of care, carotid endarterectomy (CEA).
Read More: https://www.globenewswire.com/news-release/2019/11/22/1951528/0/en/Favorable-Outcomes-with-TCAR-vs-Carotid-Endarterectomy-in-Patients-with-Carotid-Artery-Disease.html
BCBS of Minnesota inks deal with Omada to provide Type 2 diabetes tool to members
Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference
Results from Prospective, Multicenter Trial Evaluating the Use of the Tablo® Hemodialysis System for Home Dialysis Released at the American Society of Nephrology Scientific Meeting
Via: PR Newswire
First New Device Trial Completed for Home Hemodialysis In 15 Years
SUNNYVALE, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2019.
FreeStyle Libre's glucose readings, trends and patterns will all be incorporated into Omada's app.
Alongside a deeper collaboration with the not-for-profit system, Omada expects the funds to fuel expansion of its integrated digital care program.
Via: Carilion Clinic
Joe Wright of Wytheville went to his ophthalmologist with a case of pink eye. What Joe, 83, came away with was, in his own words, “a pretty big shock.”
Via: Yahoo! Finance
Nearly 800,000 Americans have a stroke each year. Sadly, about 140,000 of them will pass away from the event. That makes stroke the fifth most common cause of death. These numbers speak volumes about our desperate need for new treatment options.
Silk Road Medical Announces Closing of Follow-on Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SUNNYVALE, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the closing of a public offering of 4,200,000 shares of its common stock sold by selling stockholders, and the exercise in full of the underwriters’ option to purchase 630,000 additional shares of common stock from certain selling stockholders, at a public offering price of $39.50 per share. Silk Road Medical did not receive any proceeds from the sale of the shares of common stock by the selling stockholders.